FDA has approved Fotivda (tivozanib), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.
FDA has granted accelerated approval to Yescarta (axicabtagene ciloleucel) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Health Canada has approved Keytruda (pembrolizumab), for the first-line treatment, as monotherapy, for adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Surface Oncology and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Surface’s SRF388, an investigational antibody therapy targeting IL-27, with Merck’s Keytruda (pembrolizumab), an anti-PD-1 therapy.
Syapse has renewed its strategic collaboration with Pfizer.
Last year, Fox Chase Cancer Center stood poised to make history by becoming the first NCI-designated cancer center to be sold on open market.
Three companies withdraw cancer indications for PD-1/PD-L1 drugs in FDA’s “industry-wide evaluation”
Over the past three months, three pharmaceutical companies voluntarily withdrew three cancer indications for drugs that had previously received accelerated approvals from FDA, but ultimately failed to meet agreed-upon endpoints in confirmatory trials required for regular approvals.
Once an expensive cancer drug is discarded, it’s not worth it for drug developers, health care providers, and payers to recoup its cost, the National Academies of Sciences, Engineering, and Medicine said in a congressionally mandated report.
Hans Clevers will receive the the Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research at the 2021 virtual AACR annual meeting.
Sarah Hawley was named associate director for training, education and career development at the University of Michigan Rogel Cancer Center.
